This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Efaproxyn

Spectrum Pharmaceuticals, Inc.

Drug Names(s): RSR13, Efaproxiral, Revaproxyn

Description: An IV-infusion therapy that increases the oxygen-carrying capacity of hemoglobin while simultaneously inducing cytotoxic effects and providing neuroprotection. Researchers believe that the adjuvant use of a radiosensitizing agent such as efaproxiral can alter the treatment landscape for those patients, partially because it does not have to cross the blood-brain barrier to be effective.

RSR13 binds to hemoglobin (Hb), reduces oxygen (O2) binding affinity, and enhances O2 unloading from Hb to hypoxic tissue. Tissue hypoxia is common to cancer, surgery, myocardial ischemia, and stroke. RSR13 increases tumor pO2, reduces tumor hypoxic fraction and because O2 is necessary to maximize the effectiveness of radiation therapy, RSR13 enhances the efficacy of radiation therapy.

Deal Structure: Allos and Spectrum
In April 2012, Spectrum and Allos announced that they have signed a definitive agreement under which Spectrum will acquire all of the outstanding shares of Allos for $1.82 per share in cash plus one Contingent Value Right (CVR). In September 2012, Spectrum completed its acquisition of Allos.


Efaproxyn News

Pink Sheet Allos CEO resigns


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug